The study design includes an observational prospective cohort of HIV-positive pregnant/postpartum women and their infants enrolled during antenatal clinics (or immediately postpartum) from prevention of mother-to-child transmission (PMTCT) programs and followed until the infants reach the age of 18 - 24 months and semi-structure interviews with a sub-set of these women. A second study component involves semi-structured interviews with health care workers (HCW) involved in the PMTCT programs and yearly facility surveys at the selected study facilities.
Study Type
OBSERVATIONAL
Enrollment
1,216
Elizabeth Glaser Pediatric AIDS Foundation
Kigali, Rwanda
18 - 24 month HIV-free survival of children born to HIV-positive pregnant women
Time frame: 18 - 24 months
HIV-exposed infants with stunting, underweight, or wasting Infants and young children breastfed (exclusive or any breastfeeding) at various ages
Time frame: 18 - 24 months
Infants and young children breastfed (exclusive or any breastfeeding) at various ages
Time frame: 18 - 24 months
Adherence to the universal antiretroviral therapy (ARV) regimen among pregnant and postpartum women (Option B+) and their HIV-exposed children, including the proportion of study women with HIV RNA < 1000 copies/ml or > 2 log10 copies/mL decrease in viral
Time frame: 18 - 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.